Immuneering Corporation Stock price

Equities

IMRX

US45254E1073

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
2.89 USD +18.93% Intraday chart for Immuneering Corporation +5.86% -60.68%
Sales 2024 * - Sales 2025 * - Capitalization 84.63M
Net income 2024 * -72M Net income 2025 * -94M EV / Sales 2024 * -
Net cash position 2024 * 49.3M Net cash position 2025 * 65.92M EV / Sales 2025 * -
P/E ratio 2024 *
-1.53 x
P/E ratio 2025 *
-1.55 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.36%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Immuneering Corporation

1 day+18.93%
1 week+5.86%
Current month-53.39%
1 month-54.49%
3 months-62.95%
6 months-63.09%
Current year-60.68%
More quotes
1 week
2.26
Extreme 2.26
2.97
1 month
1.90
Extreme 1.9
7.68
Current year
1.90
Extreme 1.9
7.68
1 year
1.90
Extreme 1.9
14.29
3 years
1.90
Extreme 1.9
33.99
5 years
1.90
Extreme 1.9
33.99
10 years
1.90
Extreme 1.9
33.99
More quotes
Managers TitleAgeSince
Founder 42 07-12-31
Director of Finance/CFO 40 21-04-30
Chief Administrative Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 21-04-26
Founder 79 07-12-31
Director/Board Member 71 21-06-30
More insiders
Date Price Change Volume
24-03-28 2.89 +18.93% 962,839
24-03-27 2.43 +1.67% 705,205
24-03-26 2.39 -5.53% 622,621
24-03-25 2.53 -0.78% 480,222
24-03-22 2.55 -6.59% 707,360

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.89 USD
Average target price
16.86 USD
Spread / Average Target
+483.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Immuneering Corporation - Nasdaq